Skip to main content

Research Repository

Advanced Search

All Outputs (954)

Abnormal acinar–β-cell crosstalk in type 2 diabetes (2023)
Journal Article
Geravandi, S., & Ardestani, A. (2023). Abnormal acinar–β-cell crosstalk in type 2 diabetes. Trends in Endocrinology & Metabolism, 34(11), 685-687. https://doi.org/10.1016/j.tem.2023.08.006

Cellular crosstalk plays a vital role in maintaining pancreas homeostasis. Recently, in Cell Metabolism, Basile et al. demonstrated that aberrant upregulation of acinar-cell-specific pancreatic elastase CELA3B within endocrine islets reduces β-cell v... Read More about Abnormal acinar–β-cell crosstalk in type 2 diabetes.

Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide (2023)
Journal Article
Molica, S., Rossi, M., & Allsup, D. (2023). Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide. Acta Haematologica, 147(3), 257-259. https://doi.org/10.1159/000533349

In addition to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines that are reference standards for the treatment of chronic lymphocytic leukemia (CLL) in Europe and the USA, several consensus... Read More about Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide.

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (2023). Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. Cancers, 15(14), Article 3737. https://doi.org/10.3390/cancers15143737

Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is, howev... Read More about Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.

Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) (2023)
Journal Article
Alwan, N. A., Clutterbuck, D., Pantelic, M., Hayer, J., Fisher, L., Hishmeh, L., Heightman, M., Allsopp, G., Wootton, D., Khan, A., Hastie, C., Jackson, M., Rayner, C., Brown, D., Parrett, E., Jones, G., Smith, K., Clarke, R., McFarland, S., Gabbay, M., …Cleary, N. (2023). Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways). PLoS ONE, 18(7 July), Article e0284297. https://doi.org/10.1371/journal.pone.0284297

Background and aim Long Covid is a significant public health concern with potentially negative implications for health inequalities. We know that those who are already socially disadvantaged in society are more exposed to COVID-19, experience the wor... Read More about Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways).

A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis (2023)
Journal Article
Morris, V., Ghazi, H., Fletcher, D., & Guinn, B. A. (2023). A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 24(11), Article 9667. https://doi.org/10.3390/ijms24119667

Acute myeloid leukaemia (AML) is characterized by impaired myeloid differentiation resulting in an accumulation of immature blasts in the bone marrow and peripheral blood. Although AML can occur at any age, the incidence peaks at age 65. The pathobio... Read More about A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.

Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer. (2023)
Presentation / Conference Contribution
Nikitenko, L. L., Manolis, D., O'Brien, D. P., Adekeye, A., Kessler, B. M., Collins, C., Kramer, H., Chang, D., & Maraveyas, A. Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer. Presented at The London Pancreas Workshop 2023, London, United Kingdom

In our EARLY DIAgnosis of PAncreatic Cancer (EARLY DIAPAC) study, we aim to analyse molecular changes or “signatures” associated with early stages of pancreatic carcinogenesis by using the combination of: (i) Label-Free Quantitative Proteomics (LFQP)... Read More about Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer..

A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells (2023)
Journal Article
Guinn, B. A., Schuler, P. J., Schrezenmeier, H., Hofmann, S., Weiss, J., Bulach, C., …Greiner, J. (2023). A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells. International Journal of Molecular Sciences, 24(11), Article 9285. https://doi.org/10.3390/ijms24119285

Immune checkpoint inhibitors can block inhibitory molecules on the surface of T cells, switching them from an exhausted to an active state. One of these inhibitory immune checkpoints, programmed cell death protein 1 (PD-1) is expressed on T cell subp... Read More about A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial (2023)
Journal Article
Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., Walewska, R., Furtado, M., Preston, G., Neilson, J. R., Pemberton, N., Sidra, G., Morley, N., Cwynarski, K., Schuh, A., Forconi, F., Elmusharaf, N., Paneesha, S., Fox, C. P., Howard, D. R., …Munir, T. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The lancet oncology, 24(5), 535-552. https://doi.org/10.1016/S1470-2045%2823%2900144-4

Background: The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludara... Read More about Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

The Host-Microbiota Axis in Chronic Wound Healing (2023)
Thesis
Stafford, A. R. The Host-Microbiota Axis in Chronic Wound Healing. (Thesis). Hull York Medical School. https://hull-repository.worktribe.com/output/4424929

Chronic, non-healing skin wounds represent a substantial area of unmet clinical need, leading to debilitating morbidity and mortality in affected individuals. Due to their high prevalence and recurrence, chronic wounds pose a significant economic bur... Read More about The Host-Microbiota Axis in Chronic Wound Healing.

Factor VII deficiency: a cause of (or risk factor for) bleeding? (2023)
Journal Article
Hampshire, D. J. (2023). Factor VII deficiency: a cause of (or risk factor for) bleeding?. British journal of haematology, 202(3), 457-458. https://doi.org/10.1111/bjh.18806

Among the rare bleeding disorders factor VII deficiency is the most common, but correlating deficiency with bleeding phenotype is challenging. In their study Lou and colleagues investigate a large cohort of unrelated factor VII deficient patients pro... Read More about Factor VII deficiency: a cause of (or risk factor for) bleeding?.

An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies (2023)
Journal Article
Khan, S., Allsup, D., & Molica, S. (2023). An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies. Frontiers in Oncology, 13, Article 1135812. https://doi.org/10.3389/fonc.2023.1135812

Chronic lymphocytic leukaemia (CLL) is a malignancy of clonally expanded antigen-switched, neoplastic, mature B cells. CLL is characterised by a variable degree of immunosuppression and secondary hypogammaglobulinemia. B-cell depleting therapies have... Read More about An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies.

Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol (2023)
Journal Article
Baldwin, Z.-A., Busby, S., Allsup, D., Cohen, J., & Bamidele, O. (2023). Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol. PLoS ONE, 18(3), Article e0282458. https://doi.org/10.1371/journal.pone.0282458

Introduction Haematological malignancies are a heterogenous group of blood and lymphatic cancers. Survivorship care is a similarly diverse term concerning patients’ health and wellbeing from diagnosis to end of life. Survivorship care for patients wi... Read More about Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol.

The Skin Microbiome: Current Landscape and Future Opportunities (2023)
Journal Article
Smythe, P., & Wilkinson, H. N. (2023). The Skin Microbiome: Current Landscape and Future Opportunities. International Journal of Molecular Sciences, 24(4), Article 3950. https://doi.org/10.3390/ijms24043950

Our skin is the largest organ of the body, serving as an important barrier against the harsh extrinsic environment. Alongside preventing desiccation, chemical damage and hypothermia, this barrier protects the body from invading pathogens through a so... Read More about The Skin Microbiome: Current Landscape and Future Opportunities.

Detection of microplastics in human saphenous vein tissue using μFTIR: a pilot study (2023)
Journal Article
Rotchell, J. M., Jenner, L. C., Chapman, E., Bennett, R., Bolanle, I. O., Loubani, M., Sadofsky, L., & Palmer, T. (2023). Detection of microplastics in human saphenous vein tissue using μFTIR: a pilot study. PLoS ONE, 18(2), Article e0280594. https://doi.org/10.1371/journal.pone.0280594

Microplastics (MPs) are ubiquitous in the environment, in the human food chain, and have been recently detected in blood and lung tissues. To undertake a pilot analysis of MP contamination in human vein tissue samples with respect to their presence (... Read More about Detection of microplastics in human saphenous vein tissue using μFTIR: a pilot study.

Multi-dimensional experimental and computational exploration of metabolism pinpoints complex probiotic interactions (2023)
Journal Article
Zampieri, G., Efthimiou, G., & Angione, C. (2023). Multi-dimensional experimental and computational exploration of metabolism pinpoints complex probiotic interactions. Metabolic Engineering, 76, 120-132. https://doi.org/10.1016/j.ymben.2023.01.008

Multi-strain probiotics are widely regarded as effective products for improving gut microbiota stability and host health, providing advantages over single-strain probiotics. However, in general, it is unclear to what extent different strains would co... Read More about Multi-dimensional experimental and computational exploration of metabolism pinpoints complex probiotic interactions.

Accuracy and utility of blood and urine biomarkers for the noninvasive diagnosis of endometriosis: a systematic literature review and meta-analysis (2022)
Journal Article
Dolińska, W., Draper, H., Othman, L., Thompson, C., Girvan, S., Cunningham, K., …Guinn, B. A. (2023). Accuracy and utility of blood and urine biomarkers for the noninvasive diagnosis of endometriosis: a systematic literature review and meta-analysis. F&S Reviews, 4(2), 116-130. https://doi.org/10.1016/j.xfnr.2022.12.001

Objective: Endometriosis is a chronic, incurable condition associated with debilitating pain and subfertility affecting over 190 million women worldwide, which has no reliable noninvasive diagnostic tool. We aimed to determine the state-of-the-art in... Read More about Accuracy and utility of blood and urine biomarkers for the noninvasive diagnosis of endometriosis: a systematic literature review and meta-analysis.

Machine learning-based predictions of gamma passing rates for virtual specific-plan verification based on modulation maps, monitor unit profiles, and composite dose images (2022)
Journal Article
Quintero, P., Benoit, D., Cheng, Y., Moore, C., & Beavis, A. (2022). Machine learning-based predictions of gamma passing rates for virtual specific-plan verification based on modulation maps, monitor unit profiles, and composite dose images. Physics in Medicine and Biology, 67(24), Article 245001. https://doi.org/10.1088/1361-6560/aca38a

Machine learning (ML) methods have been implemented in radiotherapy to aid virtual specific-plan verification protocols, predicting gamma passing rates (GPR) based on calculated modulation complexity metrics because of their direct relation to dose d... Read More about Machine learning-based predictions of gamma passing rates for virtual specific-plan verification based on modulation maps, monitor unit profiles, and composite dose images.